Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursodeoxycholic Acid in Polycystic Liver Disease
NCT02021110Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2013
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of ursodeoxycholic acid in Polycystic liver disease (PLD) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Proportional change of total liver volume at 24 weeks. Started Dec 2013; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
Polycystic liver disease (PLD)
Beyond the preview
Go deeper on NCT02021110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02021110.